Helius Medical Technologies (Nasdaq:HSDT) - Cotización, noticias y análisis

Resumen de acción HSDT

Helius Medical Technologies, Inc. es una empresa de neurotecnología centrada en el desarrollo, la concesión de licencias y la adquisición de tecnologías no implantables para el tratamiento de los síntomas causados por enfermedades neurológicas o traumatismos.

Acerca de la empresa

Análisis fundamental de HSDT
Puntuación del snowflake
Valoración	1/6
Crecimiento futuro	2/6
Rendimiento pasado	0/6
Salud financiera	4/6
Dividendos	0/6

Recompensas

Revenue is forecast to grow 32.37% per year

Earnings have grown 4% per year over the past 5 years

Análisis de riesgos

Earnings are forecast to decline by an average of 29.7% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($2M)

Has less than 1 year of cash runway

+ 3 riesgos adicionales

Competidores de Helius Medical Technologies, Inc.

QHSLab

OTCPK:USAQ

US$1.8m

Tivic Health Systems

NasdaqCM:TIVC

US$1.9m

Escalon Medical

OTCPK:ESMC

US$1.3m

Nuwellis

NasdaqCM:NUWE

US$2.5m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Helius Medical Technologies
Precios históricos de las acciones
Precio actual de la acción	US$0.51
Máximo en las últimas 52 semanas	US$9.50
Mínimo de 52 semanas	US$0.37
Beta	1.62
1Cambio en 1 mes	-8.00%
Variación en 3 meses	-24.48%
Cambio de 1 año	-93.58%
3Variación en 3 años	-99.91%
Variación en 5 años	-99.97%
Variación desde la OPV	-100.00%

Noticias y actualizaciones recientes

Recent updates

Helius Medical Technologies: A Net-Net Meme Stock In The Making

Aug 23

Helius Medical Technologies stock slides 51% after pricing $18M securities offering

Aug 05

We Think Helius Medical Technologies (NASDAQ:HSDT) Needs To Drive Business Growth Carefully

Aug 18

Rentabilidad de los accionistas

	HSDT	US Medical Equipment	Mercado US
7D	6.0%	0.2%	-1.6%
1Y	-93.6%	25.8%	30.8%

Rentabilidad vs. Industria: HSDT underperformed the US Medical Equipment industry which returned 25.8% over the past year.

Rentabilidad vs. Mercado: HSDT underperformed the US Market which returned 30.8% over the past year.

Volatilidad de los precios

Is HSDT's price volatile compared to industry and market?
HSDT volatility
HSDT Average Weekly Movement	19.8%
Medical Equipment Industry Average Movement	8.0%
Market Average Movement	6.0%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	2.9%

Precio estable de las acciones: HSDT's share price has been volatile over the past 3 months compared to the US market.

Volatilidad a lo largo del tiempo: HSDT's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2014	22	Dane Andreeff	heliusmedical.com

Helius Medical Technologies, Inc. es una empresa de neurotecnología dedicada al desarrollo, concesión de licencias y adquisición de tecnologías no implantables para el tratamiento de síntomas causados por enfermedades neurológicas o traumatismos. El producto de la empresa es el Estimulador Neuromodulador Portátil, un dispositivo médico no quirúrgico destinado al tratamiento a corto plazo del déficit de la marcha debido a los síntomas de la esclerosis múltiple y del déficit de equilibrio debido a lesiones cerebrales traumáticas de leves a moderadas, así como para su uso junto con ejercicio terapéutico supervisado. Helius Medical Technologies, Inc. se constituyó en 2014 y tiene su sede en Newtown, Pensilvania.

Resumen de fundamentos de Helius Medical Technologies, Inc.

¿Cómo se comparan los beneficios e ingresos de Helius Medical Technologies con su capitalización de mercado?
Estadísticas fundamentales de HSDT
Capitalización bursátil	US$1.81m
Beneficios(TTM)	-US$8.84m
Ingresos (TTM)	US$594.00k

3.0x

Ratio precio-ventas (PS)

-0.2x

Ratio precio-beneficio (PE)

¿Está HSDT sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de HSDT
Ingresos	US$594.00k
Coste de los ingresos	US$518.00k
Beneficio bruto	US$76.00k
Otros gastos	US$8.91m
Beneficios	-US$8.84m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-2.47
Margen bruto	12.79%
Margen de beneficio neto	-1,487.54%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado HSDT a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción HSDT

Recompensas

Análisis de riesgos

Competidores de Helius Medical Technologies, Inc.

OTCPK:USAQ

US$1.8m

NasdaqCM:TIVC

US$1.9m

OTCPK:ESMC

US$1.3m

NasdaqCM:NUWE

US$2.5m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Helius Medical Technologies, Inc. Announces Pons Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

Recent updates

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Helius Medical Technologies, Inc. Announces Pons Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

Helius Medical Technologies, Inc. to Report Q1, 2024 Results on May 13, 2024

Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center

Helius Medical Technologies, Inc. has filed a Follow-on Equity Offering.

Helius Medical Technologies Receives Written Notice from the Nasdaq Stock Market

Helius Medical Technologies, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients

Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital

Helius Medical Technologies, Inc. Announces Impairment Charges for the Three Months Ended September 30 2023

Helius Medical Technologies, Inc. Announces Study Results Demonstrating That PoNS Therapy(TM) Helps Patients with Traumatic Brain Injury Return to Work

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. Provides Financial Guidance for the Third Quarter of 2023

Helius Medical Technologies, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Helius Medical Technologies, Inc. Compliant with All Applicable Nasdaq Listing Criteria

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Helius Medical Technologies, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Helius Medical Technologies, Inc. to Report Q1, 2023 Results on May 11, 2023

Helius Medical Technologies to Showcase PoNS Therapy™ at American Physical Therapy Association’s 2023 Combined Sections Meeting

Helius Medical Technologies, Inc. Provides Revenue Guidance for the fourth quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Forth Quarter and Full Year Ended December 31, 2022

Helius Medical Technologies, Inc. Reports Impairment Results for the Quarter Ended September 30, 2022

Helius Medical Technologies, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Helius Medical Technologies Receives Non-Compliance Notice from Nasdaq

Helius Medical Technologies: A Net-Net Meme Stock In The Making

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Third Quarter for 2022

Helius Medical Technologies, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Helius Medical Technologies stock slides 51% after pricing $18M securities offering

Helius Medical Technologies, Inc. Announces Online Training for PoNS Therapy

Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

Helius Medical Technologies, Inc. Provides Earnings Guidance for the Second Quarter of 2022

Helius Medical Technologies, Inc. to Report Q1, 2022 Results on May 12, 2022

Helius Medical Technologies, Inc. Introduces Device in U.S. to Help Multiple Sclerosis Patients Improve Walking Ability

Helius Medical Technologies, Inc., Annual General Meeting, May 23, 2022

Helius Medical Technologies, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2021

Helius Medical Technologies, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Helius Medical Technologies Announces Voluntary De-Listing from Toronto Stock Exchange

Second quarter 2021 earnings released: US$2.58 loss per share (vs US$2.90 loss in 2Q 2020)

We Think Helius Medical Technologies (NASDAQ:HSDT) Needs To Drive Business Growth Carefully

Consensus revenue estimates fall to US$333.0k

Helius Medical makes CEO, CFO appointments

Helius Medical Technologies, Inc. Provides Revenue Guidance for the Second Quarter of 2021

Helius Medical Technologies, Inc. Not Providing Earnings Guidance for 2021, Due to COVID-19

Helius Medical Technologies, Inc. Appoints Sherrie Perkins to the Board of Directors

Helius Medical Technologies, Inc. Not to Provide Formal Financial Outlook for the Full Year 2021 At This Time

Full year 2020 earnings released: US$11.80 loss per share (vs US$12.99 loss in FY 2019)

Revenue and earnings beat expectations

Helius Medical Technologies, Inc. to Report Q4, 2020 Results on Mar 10, 2021

Helius Medical Technologies, Inc. has completed a Composite Units Offering in the amount of $9.599981 million.

Helius Medical Technologies, Inc. Regains Compliance with Nasdaq Listing Standards

Helius Medical Technologies, Inc. Submits Response to U.S. FDA in Pursuit of De Novo Classification and Clearance of the Ponstm Device for the Treatment of Gait Deficit Due to Symptoms of Multiple Sclerosis

Helius Medical Technologies announces reverse stock split

Revenue beats expectations, earnings disappoint

Third quarter 2020 earnings released: US$0.077 loss per share